These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 22388933)

  • 1. Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
    Goyenvalle A; Babbs A; Wright J; Wilkins V; Powell D; Garcia L; Davies KE
    Hum Mol Genet; 2012 Jun; 21(11):2559-71. PubMed ID: 22388933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
    Goyenvalle A; Davies KE
    Methods Mol Biol; 2011; 709():179-96. PubMed ID: 21194028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.
    Le Hir M; Goyenvalle A; Peccate C; Précigout G; Davies KE; Voit T; Garcia L; Lorain S
    Mol Ther; 2013 Aug; 21(8):1551-8. PubMed ID: 23752313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
    Goyenvalle A; Wright J; Babbs A; Wilkins V; Garcia L; Davies KE
    Mol Ther; 2012 Jun; 20(6):1212-21. PubMed ID: 22354379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
    Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
    Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
    Goyenvalle A; Babbs A; Powell D; Kole R; Fletcher S; Wilton SD; Davies KE
    Mol Ther; 2010 Jan; 18(1):198-205. PubMed ID: 19844193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
    Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
    Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.
    Le Guiner C; Montus M; Servais L; Cherel Y; Francois V; Thibaud JL; Wary C; Matot B; Larcher T; Guigand L; Dutilleul M; Domenger C; Allais M; Beuvin M; Moraux A; Le Duff J; Devaux M; Jaulin N; Guilbaud M; Latournerie V; Veron P; Boutin S; Leborgne C; Desgue D; Deschamps JY; Moullec S; Fromes Y; Vulin A; Smith RH; Laroudie N; Barnay-Toutain F; Rivière C; Bucher S; Le TH; Delaunay N; Gasmi M; Kotin RM; Bonne G; Adjali O; Masurier C; Hogrel JY; Carlier P; Moullier P; Voit T
    Mol Ther; 2014 Nov; 22(11):1923-35. PubMed ID: 25200009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
    Goyenvalle A; Babbs A; van Ommen GJ; Garcia L; Davies KE
    Mol Ther; 2009 Jul; 17(7):1234-40. PubMed ID: 19455105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering U7snRNA gene to reframe transcripts.
    Goyenvalle A
    Methods Mol Biol; 2012; 867():259-71. PubMed ID: 22454067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.
    Walmsley GL; Arechavala-Gomeza V; Fernandez-Fuente M; Burke MM; Nagel N; Holder A; Stanley R; Chandler K; Marks SL; Muntoni F; Shelton GD; Piercy RJ
    PLoS One; 2010 Jan; 5(1):e8647. PubMed ID: 20072625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
    Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
    Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice.
    Denti MA; Incitti T; Sthandier O; Nicoletti C; De Angelis FG; Rizzuto E; Auricchio A; Musarò A; Bozzoni I
    Hum Gene Ther; 2008 Jun; 19(6):601-8. PubMed ID: 18500943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting
    Wein N; Dunn DM; Waldrop MA; Gushchina LV; Frair EC; Weiss RB; Flanigan KM
    Hum Gene Ther; 2021 Nov; 32(21-22):1346-1359. PubMed ID: 34060935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.